Luye Pharmaceutical rose more than 7%, and the company's new drugs were approved for marketing in November

As of the close of trading on November 18, Luye Pharmaceutical rose more than 7% to 7.
8%, and since November, the stock has risen by about 66%, during which it ushered in 6 consecutive gains
.
Since the beginning of this month, Luye Pharma has achieved fruitful innovation results, and a number of new drugs have been approved for marketing, including domestic dessulsumab injection, China's original antidepressant new drug Ruoxinlin, etc
.
On November 10, the company announced that its holding subsidiary Boan Biotech independently developed denosumab injection (trade name: Boyoube) was approved for marketing for osteoporosis in postmenopausal women at high risk of fracture, which is the first domestic denosumab injection approved for marketing
.
Clinical evidence shows that the drug can continue to increase bone density in patients with osteoporosis and reduce the risk of vertebral, non-vertebral and hip fractures, and has good safety and good market prospects
.
Frost & Sullivan reported that the market size of denosumab for osteoporosis in China is expected to reach 7.
8 billion yuan in 2030.

On November 3, the company reported that its self-developed class 1 innovative drug Toludi venlafaxine hydrochloride sustained-release tablets (trade name: Ruoxinlin) was officially approved for the treatment of depression
.
According to clinical studies, Ruoxinlin can comprehensively and stably treat depression, significantly improve anxiety state, block/fatigue symptoms, anhedonia and cognitive ability, promote the recovery of social functions, and has good safety and tolerability, does not cause drowsiness, does not affect sexual function, weight and lipid metabolism, and is expected to bring more treatment options
to domestic patients with depression.
In addition to the domestic desulsumab injection and China's original antidepressant new drug Ruoxinlin, Luye Pharmaceutical also has a number of new drugs actively promoting the marketing progress
.
As announced by the company on November 21, the key clinical trial of paliprazone palmitate sustained-release suspension injection (LY 03010), a new drug developed by the group for the treatment of schizophrenia and schizoaffective disorder, has completed data analysis, and the results show that the preset endpoint has been reached, and based on the results of communication with the FDA in the early stage, LY 03010 plans to submit a new drug application (NDA) to the US Food and Drug Administration (FDA) through the 505 (b) (2)
route 。 THE TRIAL RESULTS SHOWED THAT LY 03010 USES AN OPTIMIZED INITIAL DOSING REGIMEN, WHICH IS BIOEQUIVALENT TO THE INITIAL DOSING REGIMEN OF INVEGA SUSTENNA, AND IS WELL TOLERATED WHEN MULTIPLE DOSING REACHES STEADY STATE, AND CAN FURTHER FACILITATE DOSING AND IMPROVE COMPLIANCE
.
According to the data, Luye Pharmaceutical is an international pharmaceutical company dedicated to the research and development, production and sales of innovative drugs, focusing on the central nervous system, tumor and other disease fields
.
The company's main products include paclitaxel-based preparations for chemotherapy for cancer, injectable compounds for radiation therapy for solid tumors, traditional Chinese medicines for the treatment of hyperlipidemia, acarbose capsules for the treatment of type 2 diabetes, and transdermal rivastigmine patches for the treatment of Alzheimer's disease
.
According to the 2022 fiscal year interim report, the company achieved operating income of 2.
851 billion yuan from January 1 to June 30 this year, down 3.
42% year-on-year, net profit attributable to the parent company was 297 million yuan, down 23.
17% year-on-year, and basic earnings per share were 0.
09 yuan
.
However, the company has continued to make efforts in R&D investment, and has gradually changed from the growth momentum formed by mergers and acquisitions to the growth momentum
formed by endogenous R&D and innovation.
In 2021, the company's total R&D investment was RMB1.
5 billion, an increase of nearly 20%
over the previous year.
Disclaimer: Under no circumstances does the information or opinions expressed herein constitute investment advice
to anyone.